What is the Global Psoriasis Coalition?
How is the Coalition linked to psoriasis advocacy?
In 2014, the World Health Organization approved Resolution WHA67.9 on Psoriasis. This Resolution officially identified psoriasis as an NCD. Two years later, the WHO published a follow-up Global Report on Psoriasis, with a range of recommendations on what the world can do to improve living conditions for people with psoriasis.
These two documents were major psoriasis advocacy successes. But IFPA wants to make sure the journey doesn’t stop there: these successes need to be followed up. That’s why the Global Psoriasis Coalition was created: to take the next step.
What is the goal of the Coalition?
The Global Psoriasis Coalition wants to focus the global health conversation on psoriasis. We believe psoriasis should be an essential item on the international NCD policy agenda.
- At the individual level, the Coalition empowers individuals to learn more about psoriasis, raise awareness in society, seek treatment and build relationships.
- At the community level, the Coalition promotes initiatives to raise the profile of psoriasis. This changes attitudes towards the disease and presents psoriasis as an essential element of any NCD policy plan.
- At the societal level, the Coalition creates partnerships to benefit patients. This ranges from improving communication between sectors to stimulating public-private research networks and advocating for holistically treating the effects of psoriasis and its comorbid NCDs.
- At the governmental level, the Coalition supports the WHO’s work on psoriasis and promotes policy interventions, such as:
– National psoriasis plans that are integrated into NCD prevention and control efforts;
– Early screening of psoriasis and its comorbidities;
– Integrating psoriasis into NCD healthcare services;
– Global awareness-raising initiatives to reduce stigma and discrimination.
Upcoming actions: Revision of WHO Global Action Plan
Policy-wise, the international community already does a great deal to address major NCDs like diabetes or heart disease. The WHO, for example, has a comprehensive “Global Action Plan for the Prevention and Control of NCDs 2013-2020.” This is great: all patients deserve better living conditions. However, in the current version of the Global Action Plan, psoriasis is nowhere to be seen.
This needs to change.
Psoriasis should be included in global and national NCD strategies not just because it affects over 125 million people worldwide. It should be included because having psoriasis strongly increases someone’s risk of developing other NCDs like diabetes and heart disease. This in turn negatively affects their life quality and increases costs for health systems.
This means that when we work to prevent and control NCDs, we should consider all NCDs – including psoriasis.
In 2018 and 2020, the WHO Global Action Plan will be revised. The Global Psoriasis Coalition will be advocating specifically to prioritize psoriasis during these revisions.
For more information, visit the Global Psoriasis Coalition website at https://www.globalpsoriasiscoalition.org/.